Allarity Financial Statements From 2010 to 2025

ALLR Stock  USD 1.05  0.02  1.94%   
Allarity Therapeutics financial statements provide useful quarterly and yearly information to potential Allarity Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Allarity Therapeutics financial statements helps investors assess Allarity Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Allarity Therapeutics' valuation are summarized below:
Gross Profit
-36.3 M
Market Capitalization
2.1 M
Revenue
-7.1 M
Earnings Share
(10.98)
Revenue Per Share
(0.02)
There are over one hundred nineteen available fundamental signals for Allarity Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Allarity Therapeutics' prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 01/18/2025, Market Cap is likely to drop to about 3.1 M. In addition to that, Enterprise Value is likely to drop to about 4.9 M
Check Allarity Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Allarity Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 543.9 K, Interest Income of 36.2 K or Depreciation And Amortization of 31.6 K, as well as many indicators such as Price To Sales Ratio of 312, Dividend Yield of 0.0 or Days Sales Outstanding of 4.8 K. Allarity financial statements analysis is a perfect complement when working with Allarity Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Allarity Therapeutics Correlation against competitors.
To learn how to invest in Allarity Stock, please use our How to Invest in Allarity Therapeutics guide.

Allarity Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Other Current Liabilities6.5 M5.1 M6.7 M
Pretty Stable
Total Current Liabilities11.7 M12.8 M12.5 M
Pretty Stable
Accounts Payable5.5 M9.7 M4.4 M
Slightly volatile
Net Receivables808.8 K851.4 KM
Slightly volatile
Total Current Assets1.7 M1.8 M7.2 M
Slightly volatile
Common Stock1.7 K1.8 K975.1 K
Slightly volatile
Property Plant Equipment18 K18.9 K416.7 K
Pretty Stable
Other Liabilities298.4 K314.1 K20.4 M
Slightly volatile
Total Assets10.1 M10.7 M27.9 M
Slightly volatile
Short and Long Term Debt TotalM1.5 M1.3 M
Slightly volatile
Property Plant And Equipment Net17.1 K18 K306.1 K
Slightly volatile
Cash141.9 K149.4 K2.3 M
Pretty Stable
Non Current Assets Total17.3 M8.9 M24.3 M
Slightly volatile
Cash And Short Term Investments141.9 K149.4 K2.3 M
Pretty Stable
Common Stock Shares Outstanding2.4 B2.3 B417.7 M
Slightly volatile
Liabilities And Stockholders Equity10.1 M10.7 M27.9 M
Slightly volatile
Non Current Liabilities Total381.3 K401.4 K4.6 M
Slightly volatile
Other Current Assets726 K987.9 K405.1 K
Slightly volatile
Total Liabilities16.6 M16.8 M12.8 M
Slightly volatile
Long Term Investments488.4 K402.5 K259.7 K
Slightly volatile
Property Plant And Equipment Gross17.1 K18 K529.3 K
Slightly volatile
Short and Long Term Debt1.6 M1.5 MM
Slightly volatile
Capital Stock1.7 MM1.2 M
Slightly volatile
Short Term Debt1.4 M1.5 M923.5 K
Slightly volatile
Intangible Assets16.9 M8.9 M23.8 M
Slightly volatile
Long Term Debt1.1 M1.2 M946.8 K
Slightly volatile
Current Deferred Revenue50.4 K53.1 K6.5 M
Slightly volatile
Non Currrent Assets Other5.1 K5.4 K263.9 K
Slightly volatile
Warrants1.6 M1.8 MM
Slightly volatile
Common Stock Total Equity1.6 K1.8 KK
Slightly volatile
Capital Surpluse66.5 M74.8 M81.6 M
Slightly volatile
Deferred Long Term Liabilities1.1 M1.3 M1.4 M
Slightly volatile

Allarity Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization31.6 K33.3 K4.7 M
Slightly volatile
Selling General Administrative8.9 M11.5 MM
Slightly volatile
Other Operating Expenses17.8 M20.6 M13.2 M
Slightly volatile
Research Development8.9 MM7.2 M
Slightly volatile
Total Operating Expenses17.8 M20.6 M13.2 M
Slightly volatile
Reconciled Depreciation46.9 K27 K51.6 K
Very volatile
Cost Of Revenue31.6 K33.3 K79.6 K
Slightly volatile
Preferred Stock And Other AdjustmentsM4.5 M4.9 M
Slightly volatile
Non Recurring14.1 M15.8 M17.2 M
Slightly volatile
Non Operating Income Net Other13.5 M15.2 M16.6 M
Slightly volatile

Allarity Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings855 K900 K13.4 M
Slightly volatile
Depreciation64.7 K33.3 K65.1 K
Very volatile
End Period Cash Flow181.4 K190.9 K1.6 M
Pretty Stable
Begin Period Cash Flow2.2 M2.3 M1.9 M
Slightly volatile
Issuance Of Capital Stock18.6 M20.8 M15.4 M
Slightly volatile
Other Cashflows From Investing Activities723.6 K728.1 K941.9 K
Slightly volatile
Dividends Paid6.9 M12.6 M3.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio312329323 M
Slightly volatile
Days Sales Outstanding4.8 K4.5 K2.5 K
Slightly volatile
Invested Capital63.1 K71 K77.4 K
Slightly volatile
Stock Based Compensation To Revenue2.622.51.9949
Slightly volatile
Capex To Depreciation0.220.350.25
Very volatile
Payables Turnover0.00480.00512.5306
Slightly volatile
Sales General And Administrative To Revenue25.829.0331.6456
Slightly volatile
Research And Ddevelopement To Revenue42.4547.7552.0635
Slightly volatile
Capex To Revenue0.07280.07670.2684
Slightly volatile
Cash Per Share1.0E-41.0E-4302.8 K
Pretty Stable
Days Payables Outstanding78.5 K74.7 K17.3 K
Slightly volatile
Income Quality1.21.231.3167
Slightly volatile
Intangibles To Total Assets0.580.750.7308
Very volatile
Current Ratio0.150.161.828
Slightly volatile
Receivables Turnover0.07910.08325.6077
Pretty Stable
Graham Number0.01490.01578.1 M
Very volatile
Capex Per Share1.6 K1.8 K1.8 K
Slightly volatile
Average Receivables193.7 K184.5 K133.7 K
Slightly volatile
Revenue Per Share29.2 K27.8 K20.9 K
Slightly volatile
Interest Debt Per Share0.0010.001411 K
Very volatile
Debt To Assets0.0630.09860.0693
Slightly volatile
Days Of Payables Outstanding78.5 K74.7 K17.3 K
Slightly volatile
Ebt Per Ebit1.00.810.9643
Slightly volatile
Long Term Debt To Capitalization0.340.330.1123
Slightly volatile
Quick Ratio0.150.161.8242
Slightly volatile
Net Income Per E B T0.670.850.8013
Slightly volatile
Cash Ratio0.01280.01351.4681
Slightly volatile
Days Of Sales Outstanding4.8 K4.5 K2.5 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0246
Slightly volatile
Fixed Asset Turnover0.30.326.8693
Very volatile
Debt Ratio0.0630.09860.0693
Slightly volatile
Price Sales Ratio312329323 M
Slightly volatile
Asset Turnover0.00320.00340.0865
Slightly volatile

Allarity Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.1 M3.2 M28.4 M
Slightly volatile

Allarity Fundamental Market Drivers

Cash And Short Term Investments166 K

Allarity Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Allarity Therapeutics Financial Statements

Allarity Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Allarity Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Allarity Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Allarity Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue53.1 K50.4 K
Cost Of Revenue33.3 K31.6 K
Stock Based Compensation To Revenue 2.50  2.62 
Sales General And Administrative To Revenue 29.03  25.80 
Research And Ddevelopement To Revenue 47.75  42.45 
Capex To Revenue 0.08  0.07 
Revenue Per Share27.8 K29.2 K
Ebit Per Revenue(168.77)(160.33)

Pair Trading with Allarity Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allarity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allarity Stock

  0.75EQ EquilliumPairCorr
  0.83ME 23Andme HoldingPairCorr
  0.87VALN Valneva SE ADRPairCorr

Moving against Allarity Stock

  0.87VCYT Veracyte Potential GrowthPairCorr
  0.86VCEL Vericel Corp OrdPairCorr
  0.83DRTS Alpha Tau MedicalPairCorr
  0.79DMAC DiaMedica TherapeuticsPairCorr
  0.67CDIOW Cardio DiagnosticsPairCorr
The ability to find closely correlated positions to Allarity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allarity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allarity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allarity Therapeutics to buy it.
The correlation of Allarity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allarity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allarity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allarity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Allarity Stock Analysis

When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.